[1] Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults。 Retrieved October 5, 2018, from https://www.nasdaq.com/press-rel ... athy-20181005-00751
[1] Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy. Retrieved October 4, 2018, from http://investorrelations.sarepta ... onal-congress-world
美国National Research Institute首席研究员Juan P. Frias博士表示:“GIP/GLP-1R双靶点降糖新药LY3298176的这项IIb期研究结果史无前例,血糖控制和体重减轻的效果令人印象深刻,有望成为2型糖尿病患者新的主流治疗方案。GLP-1受体激动剂的临床获益已经获得广泛证明,我们期待看到更多将GIP/GLP-1受体双重激动作用整合到一起的新分子未来可以给2型糖尿病患者带来的临床获益。”